Lupin Dirección

Dirección controles de criterios 3/4

El CEO de Lupin's es Vinita Gupta , nombrado en Sep 2013, tiene una permanencia de 10.58 años. compensación anual total es ₹109.20M, compuesta por 71.7% salario y 28.3% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.072% de las acciones de la empresa, por valor de ₹526.08M. La antigüedad media del equipo directivo y de la junta directiva es de 3.3 años y 4.1 años, respectivamente.

Información clave

Vinita Gupta

Chief Executive Officer (CEO)

₹109.2m

Compensación total

Porcentaje del salario del CEO	71.7%
Permanencia del CEO	10.6yrs
Participación del CEO	0.07%
Permanencia media de la dirección	3.3yrs
Promedio de permanencia en la Junta Directiva	4.1yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Vinita Gupta en comparación con los beneficios de Lupin?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	n/a	n/a	₹18b
Sep 30 2023	n/a	n/a	₹13b
Jun 30 2023	n/a	n/a	₹10b
Mar 31 2023	₹109m	₹78m	₹4b
Dec 31 2022	n/a	n/a	-₹3b
Sep 30 2022	n/a	n/a	₹682m
Jun 30 2022	n/a	n/a	-₹22b
Mar 31 2022	₹145m	₹145m	-₹15b
Dec 31 2021	n/a	n/a	-₹5b
Sep 30 2021	n/a	n/a	-₹7b
Jun 30 2021	n/a	n/a	₹17b
Mar 31 2021	₹128m	₹92m	₹12b
Dec 31 2020	n/a	n/a	₹11b
Sep 30 2020	n/a	n/a	-₹2b
Jun 30 2020	n/a	n/a	-₹6b
Mar 31 2020	₹128m	₹93m	-₹4b
Dec 31 2019	n/a	n/a	-₹4b
Sep 30 2019	n/a	n/a	₹3b
Jun 30 2019	n/a	n/a	₹7b
Mar 31 2019	₹15m	₹49m	₹5b
Dec 31 2018	n/a	n/a	-₹5b
Sep 30 2018	n/a	n/a	-₹931m
Jun 30 2018	n/a	n/a	₹960m
Mar 31 2018	₹172m	₹123m	₹3b

Compensación vs. Mercado: La compensación total de Vinita($USD1.31M) está por encima de la media de empresas de tamaño similar en el mercado Indian ($USD599.06K).

Compensación vs. Ingresos: La compensación de Vinita ha sido consistente con los resultados de la empresa en el último año.

CEO

Vinita Gupta (55 yo)

10.6yrs

Permanencia

₹109,200,000

Compensación

Ms. Vinita D. Gupta has been the Chief Executive Officer at Lupin Limited since September 1, 2013. Ms. Gupta serves as an Executive Director of Lupin Limited. She has been the Chairman and Chief Executive...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Vinita Gupta	CEO & Executive Director	10.6yrs	₹109.20m	0.072% ₹ 529.0m
Ramesh Swaminathan	Global CFO	4.1yrs	₹77.37m	0.00049% ₹ 3.6m
Nilesh Gupta	MD & Executive Director	no data	₹49.60m	0.22% ₹ 1.6b
Johnny Mikell	President & Global Head of Quality	5.3yrs	sin datos	sin datos
Christoph Funke	Chief Technical Operations Officer	less than a year	sin datos	sin datos
Sreeji Gopinathan	Chief Information Officer	4.5yrs	sin datos	sin datos
Shahin Fesharaki	Global Chief Scientific Officer	1.5yrs	sin datos	sin datos
Hemant Bakhru	Vice President of Investor Relations and M&A	no data	sin datos	sin datos
Sofia Mumtaz	President of Legal and Compliance of Australia	no data	sin datos	sin datos
Diana Amador-Toro	Senior Vice President of Global Compliance	2yrs	sin datos	sin datos
Shweta Munjal	VP and Global Head of Corporate Communications & Sustainability	3.3yrs	sin datos	sin datos
Fabrice Egros	President of Global Corporate Development & Growth Markets	2.2yrs	sin datos	sin datos

3.3yrs

Permanencia media

57yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 500257 se considera experimentado (3.3 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Vinita Gupta	CEO & Executive Director	no data	₹109.20m	0.072% ₹ 529.0m
Ramesh Swaminathan	Global CFO	4.1yrs	₹77.37m	0.00049% ₹ 3.6m
Nilesh Gupta	MD & Executive Director	15.5yrs	₹49.60m	0.22% ₹ 1.6b
Mark McDade	Independent Director	3.3yrs	₹1.45m	sin datos
Jean-Luc Belingard	Independent Non-Executive Director	8.5yrs	₹1.39m	sin datos
Kanwar Bir Anand	Independent Director	3.7yrs	₹1.57m	sin datos
Manju Gupta	Non-Executive Chairman of the Board	6.7yrs	₹1.45m	0.90% ₹ 6.6b
Punita Sinha	Independent Director	3.7yrs	₹1.65m	0.00011% ₹ 810.1k

4.1yrs

Permanencia media

68yo

Promedio de edad

Junta con experiencia: La junta directiva de 500257 se considera experimentada (4.1 años de antigüedad promedio).

Lupin Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Lupin Limited Announces Change in Management

Insufficient new directors

Lupin Limited, Annual General Meeting, Aug 03, 2023

Lupin Limited Announces Christine Mundkur Steps Down from Board of Directors, Effective January 1, 2023

Lupin Announces Resignation of Kamal K. Sharma from the Board of Directors

Lupin Limited Appoints Shahin Fesharaki as Global Chief Scientific Officer

Recent updates

Lupin Limited to Report Q4, 2024 Results on May 06, 2024

Lupin Limited Announces Change in Management

Lupin Limited Launches Bromfenac Ophthalmic Solution, 0.075% in the United States

Price target increased by 12% to ₹1,355

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Lupin Limited Receives Approval from U.S. FDA for Bromfenac Ophthalmic Solution, 0.075%

Insufficient new directors

Lupin Limited to Report Q3, 2024 Results on Feb 07, 2024

Lupin Receives Approval from U.S. FDA for Febuxostat Tablets

Lupin Limited Launches Bromfenac Ophthalmic Solution, 0.07% in the United States

Lupin Receives Approval from U.S. FDA for Loteprednol Etabonate Ophthalmic Suspension, 0.2%

Lupin Limited Receives Tentative Approval from U.S. FDA for Canagliflozin Tablets

Lupin Limited Launches First Fixed-Dose Triple Combination Drug, Vilfuro-G® for COPD Management in India

Lupin Limited Receives Tentative Approval from U.S. FDA for Dapagliflozin Tablets

Consensus EPS estimates increase by 14%

Price target increased by 7.3% to ₹1,058

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Lupin Limited to Report Q2, 2024 Results on Nov 08, 2023

Lupin Limited Receives Tentative Approval from U.S. FDA for Calcium, Magnesium, Potassium, and Sodium Oxybates Oral Solution

Lupin Limited (BSE:500257) completed the acquisition of Ondero and Ondero - Met from Boehringer Ingelheim International GmbH.

Price target increased by 15% to ₹878

Lupin Limited Approves Dividend for the Year Ended March 31, 2023

Girard Sharp LLP and Motley Rice LLC Announce a Proposed Settlement in re Xyrem (Sodium Oxybate) Antitrust Litigation

Girard Sharp LLP and Motley Rice LLC Announce a Proposed Settlement in In re Xyrem (Sodium Oxybate) Antitrust Litigation

Lupin Limited Receives Tentative Approval from U.S. Fda for Dolutegravir Lamivudine and Tenofovir Alafenamide Tablets

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Lupin Limited Receives EIR from U.S. FDA for its Pithampur Unit-2 Manufacturing Facility

Upcoming dividend of ₹4.00 per share at 0.4% yield

Lupin Limited, Annual General Meeting, Aug 03, 2023

Lupin Limited Receives Approval from U.S. Fda for Cyanocobalamin Nasal Spray

Lupin Limited Launches Thiamine Hydrochloride Injection USP in the United States

Lupin Launches Darunavir Tablets in the United States

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Third quarter 2023 earnings: Revenues in line with analyst expectations

Lupin Receives Approval from US FDA for Glycopyrrolate Injection, USP

Lupin Limited Receives Tentative Approval from U.S. FDA for Dolutegravir, Emtricitabine and Tenofovir Alafenamide (DETAF) Tablets

Lupin Limited to Report Q3, 2023 Results on Feb 09, 2023

Lupin Limited Launches Sacubitril and Valsartan Combination Drug for Heart Failure Patients

Lupin Receives Tentative Approval from U.S. FDA for Dolutegravir and Rilpivirine Tablets

Lupin and Exeltis Announce Reimbursement Approval of NaMuscla in Spain for the Symptomatic Treatment of Myotonia in Adults with Non-Dystrophic Myotonic Disorders

Lupin Receives Approval from U.S. FDA for Fesoterodine Fumarate Extended-Release Tablets

Lupin Limited Launches Novel Fixed-Dose Triple Drug Combination Difizma® Dpi to Treat Inadequately Controlled Asthma

Lupin Limited Announces Christine Mundkur Steps Down from Board of Directors, Effective January 1, 2023

Lupin Launches Rufinamide Tablets USP in the United States

Lupin Launches Formoterol Fumarate Inhalation Solution in the United States

Consensus forecasts updated

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Lupin Receives Tentative Approval from U.S. FDA for Doxycycline Capsules

Lupin Limited Receives Tentative Approval from U.S. FDA for Drospirenone Tablets

Lupin Limited Update on its Biotech Manufacturing Facility

Lupin Announces Resignation of Kamal K. Sharma from the Board of Directors

Lupin Limited Appoints Shahin Fesharaki as Global Chief Scientific Officer

Lupin Receives Approval from U.S. FDA for Mirabegron Extended-Release Tablets

Lupin Receives Approval from U.S. FDA for Diclofenac Sodium Topical Solution USP, 2% w/w

Lupin Receives Health Canada Approval for Rymti® (Biosimilar Etanercept)

Lupin Launches Generic Suprep® Bowel Prep Kit in the United States

Lupin Limited in Partnership with Pharmascience Inc. Receives Tentative Approval from U.S. Fda for Dasatinib Tablets

Lupin Limited Announces Launch of Desvenlafaxine Extended-Release Tablets, 25 Mg

Lupin Limited (BSE:500257) agreed to acquire Ondero and Ondero - Met from Boehringer Ingelheim International GmbH for €26 million.

Lupin Limited Receives Approval from U.S. FDA for Rufinamide Tablets USP

Lupin Limited Receives Approval from U.S. FDA for Meclizine Hydrochloride Tablets USP

Lupin Limited Declares Dividend for the Year Ended March 31, 2022

Lupin Limited Receives Approval from the United States Food and Drug Administration for Its Abbreviated New Drug Application

Lupin Limited to Report Q1, 2023 Results on Aug 03, 2022

Full year 2022 earnings: EPS misses analyst expectations

Lupin's Somerset Manufacturing Plant Receives EIR from U.S. Food and Drug Administration

Lupin Limited, Annual General Meeting, Aug 03, 2022

Lupin Limited Receives Tentative Approval from U.S. FDA for Ivacaftor Tablets

High number of new directors